MCI

Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Retrieved on: 
понедельник, апреля 1, 2024
Biogen, FDA, Brain, Administration, MCI, State, Fast Track, Dementia, Cell, Clarity, Eisai, Biologics license application, European, Alzheimer's disease, OLE, Patient, BLA, Neuron, Plaque, Lecanemab

LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment or mild dementia stage of disease (collectively referred to as early AD).

Key Points: 
  • LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment or mild dementia stage of disease (collectively referred to as early AD).
  • Eisai had aimed to submit a Biologics License Application (BLA) for weekly maintenance therapy using subcutaneous (SC) administration in March 2024.
  • However, Eisai was recently informed by the FDA that a Fast Track designation specific for the SC formulation is needed to receive rolling review.
  • Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

Lifenet and Eisai Co-Develop Dementia Insurance "be"

Retrieved on: 
четверг, марта 21, 2024
Brain, MCI, Aftercare, LINE, Learning, Dementia, Air Methods, Forgetting, Annual report, Insurance, Transport, Attention, Disease, Exercise, QR, Nursing, Prevalence, Diagnosis, Memory, Ageing, Drug discovery, Cabinet Office, Residential care

TOKYO, Mar 21, 2024 - (JCN Newswire) - LIFENET INSURANCE COMPANY and Eisai Co., Ltd. announced today that they have co-developed Dementia Insurance "be", a dementia insurance that supports early detection and treatment of dementia and mild cognitive impairment (hereafter, "MCI") as one of the initiatives under the capital and business alliance agreement concluded in August 2022 for collaboration in dementia and other areas.

Key Points: 
  • TOKYO, Mar 21, 2024 - (JCN Newswire) - LIFENET INSURANCE COMPANY and Eisai Co., Ltd. announced today that they have co-developed Dementia Insurance "be", a dementia insurance that supports early detection and treatment of dementia and mild cognitive impairment (hereafter, "MCI") as one of the initiatives under the capital and business alliance agreement concluded in August 2022 for collaboration in dementia and other areas.
  • MCI is the stage just before dementia diagnosis, where cognitive function is somewhere between the healthy and dementia states.
  • This dementia insurance product is offered by Lifenet.
  • Dementia Insurance "be" supports the early detection and treatment of dementia, increasing treatment options by providing generous coverage from the MCI stage.

Investors in Anavex Life Sciences Corporation Should Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights – AVXL

Retrieved on: 
четверг, мая 9, 2024
MCI, News, Radar, NEXT, Rett syndrome, Patient, Clinical trial, Fraud, Security (finance)

NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation (NASDAQ: AVXL).

Key Points: 
  • NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation (NASDAQ: AVXL).
  • Shareholders who purchased shares of AVXL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

ANAVEX ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Anavex Life Sciences Corp. and Encourages Investors to Contact the Firm

Retrieved on: 
четверг, мая 9, 2024
MCI, News, Radar, Rett syndrome, P.C, District court, Patient, Court, Clinical trial, Telephone, Person

Investors have until May 13, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until May 13, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • ANAVEX®2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results.
  • Biotech analysts commented that “the negative study outcome was never in doubt…Anavex is a serial dissembler of clinical trial results.”
    Following this news, AVXL’s stock price fell by $3.26 per share, or approximately 35%.

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Anavex

Retrieved on: 
среда, мая 8, 2024
MCI, LLP, News, Advertising, Radar, Avatar, Court, Clinical trial, Excellence, Cryptocurrency

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Anavex’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).

Anavex Life Sciences Corporation Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 13, 2024 to Discuss Your Rights – AVXL

Retrieved on: 
вторник, мая 7, 2024
MCI, LLP, News, CLASS, Radar, NEXT, Rett syndrome, Patient, Court, Clinical trial, Telephone, COST

NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation ("Anavex Life Sciences" or the "Company") (NASDAQ: AVXL) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation ("Anavex Life Sciences" or the "Company") (NASDAQ: AVXL) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Anavex Life Sciences investors who were adversely affected by alleged securities fraud between February 1, 2022 and January 1, 2024.
  • Follow the link below to get more information and be contacted by a member of our team:
    AVXL investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

MCI USA Welcomes Danielle Hobson as Vice President, Strategic Marketing

Retrieved on: 
вторник, мая 7, 2024
MCI, Woman, Marketing, Nielsen, Publicis Sapient, Mental health, Lead, Marketing strategy, Management

WASHINGTON, May 7, 2024 /PRNewswire-PRWeb/ -- MCI USA is pleased to welcome Danielle Hobson as Vice President, Strategic Marketing. In this newly created role, Danielle will spearhead MCI USA's strategic marketing initiatives, driving growth and brand awareness. She will lead MCI USA's professional marketing and communications team, showcasing the company's exceptional work, diverse talents, and robust partnerships.

Key Points: 
  • MCI USA is pleased to welcome Danielle Hobson as Vice President, Strategic Marketing.
  • WASHINGTON, May 7, 2024 /PRNewswire-PRWeb/ -- MCI USA is pleased to welcome Danielle Hobson as Vice President, Strategic Marketing.
  • In this newly created role, Danielle will spearhead MCI USA's strategic marketing initiatives, driving growth and brand awareness.
  • "I'm excited to join the MCI USA team and look forward to innovating with such talented people to propel our business forward and make a meaningful difference to the clients and communities we serve," said Danielle Hobson, Vice President, Strategic Marketing, MCI USA.

Contact Levi & Korsinsky by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation (AVXL)

Retrieved on: 
пятница, мая 3, 2024
MCI, LLP, News, CLASS, Radar, NEXT, Rett syndrome, Patient, Court, Clinical trial, Telephone, COST

NEW YORK, May 03, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation ("Anavex Life Sciences" or the "Company") (NASDAQ: AVXL) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, May 03, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation ("Anavex Life Sciences" or the "Company") (NASDAQ: AVXL) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Anavex Life Sciences investors who were adversely affected by alleged securities fraud between February 1, 2022 and January 1, 2024.
  • Follow the link below to get more information and be contacted by a member of our team:
    AVXL investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

MCRA Supports Darmiyan with FDA Approval for BrainSee Device

Retrieved on: 
четверг, мая 2, 2024
Alzheimer's disease, FDA, Brain, MCI, Policy, Food, Montreal Cognitive Assessment, De novo, Artificial intelligence, Digital, Science, Digital health, MCRA, MRI, Marketing, Contract research organization, Pharmaceutical industry

MCRA announces its role in the successful granting of Darmiyan's De Novo request for BrainSee by the FDA.

Key Points: 
  • MCRA announces its role in the successful granting of Darmiyan's De Novo request for BrainSee by the FDA.
  • Darmiyan retained MCRA in 2021 for its broad and deep experience in Neurology, Digital Health, and Artificial Intelligence (AI).
  • John Doucet, Vice President, Neurology Regulatory Affairs – Neuromodulation and Evolving Technologies at MCRA states, "We are proud to have worked closely with Darmiyan to achieve both Breakthrough Device Designation and marketing authorization from the FDA for BrainSee.
  • The FDA Breakthrough Device Designation for BrainSee was a critical foundation for FDA collaborations during development, review, and granting of the De Novo request.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE

Retrieved on: 
четверг, мая 2, 2024
MCI, News, LLP, Pomerantz, Sage

NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. (“Sage” or the “Company”) (NASDAQ: SAGE).

Key Points: 
  • NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. (“Sage” or the “Company”) (NASDAQ: SAGE).
  • The investigation concerns whether Sage and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.